Method for targeted application of active agents to a target surface including the steps of: (a) capturing an image of the target surface; (b) transforming the image into a digital geometric representation of the target surface; (c) forming an applicator mask having an applicator surface with a three-dimensional shape corresponding to the target surface; (d) disposing the active agent on the applicator surface of the applicator mask; (e) disposing the applicator mask on the target surface so that the active agent is in contact with the target surface; and (f) removing the applicator mask from the target surface while leaving at least some of the active agent in contact with the target surface.

The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.

A method for forming an applicator comprises steps of: creating a digital geometric representation of the structure, the target structure having a flatness ratio; forming the applicator using the digital geometric representation of the target structure, the applicator having a target structure contacting surface; and disposing an active agent upon the target structure contacting surface of the applicator.

The skin care method of skin beauty device according to the present invention can lower the skin barrier by charging negative potential to skin through mist spraying, expand pores and reproduce the skin through temperature stimulation and irradiation of red light after cleaning wastes from inside the pores, and more effectively enable cosmetics to be introduced into the skin through EP function and vibration function. Furthermore, the skin care procedures can be finished by implementing the pore shrinkage through cooling stimulation and antimicrobial action through blue light irradiation. The more efficient skin care can be realized through adequate implementation of thus-mentioned series of skin care functions according to the order, compared to individual implementations of various functions of the skin beauty device, whereby users not accustomed to the skin care can easily care the skin.

Method for targeted application of active agents to a target surface including the steps of: (a) capturing an image of the target surface; (b) transforming the image into a digital geometric representation of the target surface; (c) forming an applicator mask having an applicator surface with a three-dimensional shape corresponding to the target surface; (d) disposing the active agent on the applicator surface of the applicator mask; (e) disposing the applicator mask on the target surface so that the active agent is in contact with the target surface; and (f) removing the applicator mask from the target surface while leaving at least some of the active agent in contact with the target surface.

The invention provides systems and components thereof for ultrasound-mediated drug delivery within the GI tract delivery of therapeutic agents to the gastrointestinal tract of a subject. The systems comprise a transmitter that includes a power source and power emitter for transmitting EM and non-EM energy. The power transmitter comprises one or more capacitive, inductive, magnetic resonance. RF, or ultrasonic energy radiator. The second component is an ingestible capsule that is physically separate from the transmitter. The ingestible capsule may be configured to harvest energy from the transmitter using a variety of components. In various embodiments, the ingestible pill comprises at least one energy harvesting component, an ultrasound transducer, and a reservoir or payload that releasably retains a liquid or powder mixture containing an encapsulated or non-encapsulated therapeutic agent. When in use, the ingestible capsule enters the GI tract of the subject, while the transmitter remains external to the subject's body.

Presented herein are techniques for clinical-based automated control of the delivery of treatment substances to at least one inner ear of a recipient of an implantable medical device. More specifically, in-vivo biomarkers are analyzed to determine a biological state/status of one or more physiological elements of the inner ear. Subsequent delivery of one or more treatment substances to the inner ear of the recipient are controlled based on the determined biological state of the one or more physiological elements of the inner ear.

A system is provided for healing a wound. The system includes a flexible body, a therapeutic agent delivery mechanism, a suction mechanism, and a power source. The flexible body includes a cover film having oppositely disposed first and second surfaces that define a compartment. The compartment includes a first porous material, a second porous material, and at least one electrode disposed therein. The second porous material is disposed between the first porous material and the at least one electrode. The therapeutic agent delivery mechanism and the suction mechanism are fluidly connected to the compartment. The power source is in electrical communication with the at least one electrode.

The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.